Relay Therapeutics beat analyst estimates for both GAAP revenue and earnings per share in Q2 2025. The company reported continued clinical advancement of its lead asset RLY-2608, with new positive ...

Corvus Pharmaceuticals reported a net loss per share of $(0.10) for Q2 2025, a smaller loss than the analyst estimate of $(0.13). Research and development expenses rose sharply to $7.9 million, ...

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...

Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no ...

Cardiol Therapeutics reports topline results from phase II ARCHER trial of CardiolRx in acute myocarditis patients: Toronto, Ontario Friday, August 8, 2025, 12:00 Hrs [IST] Cardio ...

Cardiol's CardiolRx did not have a significant impact on left ventricular extracellular volume (LV-ECV) in the Phase II ARCHER study.

AbCellera Biologics (ABCL) marks a milestone, transitioning to clinical-stage biotech with ABCL635 dosing and pipeline expansion.

Q2 2025 Management View Punit S. Dhillon, President and CEO, highlighted the imminent reporting of Phase IIa data for ...

It comes amid a warning that too often this phase of someone’s life “is seen as unexpected or a last-minute crisis” ...

Cancer survival has doubled in the past half a century, but around 167,000 people still die of the disease in the UK every ...

Health and Human Services Secretary Robert F. Kennedy Jr. is cancelling 22 mRNA vaccine contracts funded by BARDA. Without evidence, Kennedy claimed these vaccines fail to protect effectively against ...